Passage BIO, Inc. Segments Disclosure
14. Segment Reporting
Operating segments are defined as components of an enterprise which engages in business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in assessing performance. The Company operates in a reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. The Company’s CODM is its chief executive officer.
The measure of segment assets is reported on the balance sheet as total assets. All assets are located within the United States.
The CODM uses net loss as reported on our statement of operations to assess the Company’s performance. Our CODM also uses cash forecast in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses exclude certain non-cash items such as share based compensation and depreciation and amortization expenses.
The following table summarizes significant segment expenses:
December 31, | ||||||
(in thousands) | 2024 |
| 2023 | |||
Research and development | ||||||
Wages, benefits and other payroll | $ | 12,265 | $ | 16,762 | ||
Third-party costs | 22,691 | 36,304 | ||||
Share-based compensation | 2,529 | 5,554 | ||||
Depreciation and amortization | 2,694 | 2,799 | ||||
Total research and development expenses | 40,179 | 61,419 | ||||
General and administrative | ||||||
Wages, benefits and other payroll | 9,255 | 11,606 | ||||
Third-party costs | 12,055 | 12,352 | ||||
Amended Catalent agreements expense | — | 11,333 | ||||
Share-based compensation | 3,291 | 5,367 | ||||
Depreciation and amortization | 387 | 922 | ||||
Total general and administrative expenses | 24,988 | 41,580 | ||||
Impairment of long-lived assets | 5,233 | 5,390 | ||||
Loss from operations | 70,400 | 108,389 | ||||
Other (income) expense, net | (5,633) | (6,327) | ||||
Net loss | $ | 64,767 | $ | 102,062 | ||
The components of Other (income) expense, net are futher described in note 3 to the financial statements.
Want the next Passage BIO, Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Passage BIO, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.